3 Under-the-Radar Stocks to Buy and Hold

Three under-the-radar biotechs highlight strong momentum: Axsome Therapeutics revenue rose 57% YoY to $191.2M in Q1 and secured a label expansion for Auvelity in Alzheimer’s agitation. Exelixis reported Q1 revenue up 10% YoY to $610.8M, while Madrigal’s Rezdiffra is on track to exceed $1B in annual sales this year. The article frames multiple near-/mid-term catalysts (phase 3 readouts, FDA decisions, and new indications) as supportive for earnings growth, though it notes Exelixis faces generic competition risk starting around 2030.

Analysis

The market mechanism here is not “biotech up on growth,” but duration re-rating: these names only work if investors believe today’s commercial run-rate is the start of a multi-year franchise, not a one-cycle launch. AXSM has the cleanest near-term operating leverage because incremental label breadth can expand physician usage without requiring a new salesforce build, while MDGL is more of a penetration story where the next leg depends on repeat prescribing and specialist conversion, not just first approvals.

Relative winners are likely the names with the least binary dependence on a single future event. EXEL already has cash generation to fund the zanzalintinib transition, which should reduce financing overhang versus pure pipeline peers; the trade is that oncology upside may be partially offset by looming 2030s patent decay and intense standard-of-care competition. In MASH, MDGL’s leadership can be fragile if payers tighten prior auth or if larger-cap obesity franchises absorb physician attention, creating a substitution risk that the article underweights.

The contrarian view is that the cluster is being treated as “good fundamentals,” but each stock has a different failure mode: AXSM needs utilization to prove the label expansion is meaningful; MDGL needs evidence that the first-mover advantage converts into durable share before competitors arrive; EXEL needs zanzalintinib to be more than a single-asset bridge. For the next 1-3 months, the key catalyst path is script data, management commentary on payer friction, and any FDA/timing updates; over 6-18 months, the issue is whether these pipelines create real earnings power or merely defer patent/cliff concerns.

Key Decisions for Investors

• Long AXSM on any post-rally consolidation; best risk/reward is a 3-6 month trade into utilization data, with the thesis invalidated if prescription growth fails to re-accelerate after the label expansion.
• Hold/accumulate EXEL only as a cash-flow-backed pipeline transition; pair it against a higher-beta oncology basket or XBI if you want exposure to the zanzalintinib catalyst without taking full single-name trial risk.
• Treat MDGL as a watchlist rather than an aggressive buy here: the stock likely needs proof of broad payer-friendly adoption, so wait for sequential script and reimbursement data before adding.
• Relative-value idea: long AXSM / short XBI for 1-3 months, betting that commercial-label expansion is less binary than broader biotech risk and should attract capital if the sector derisks.
• Set alerts for the next quarterly script trends and any FDA timing changes; if AXSM or MDGL show plateauing new starts, the growth premium should compress quickly.